Biotechnology The Food and Drug Administration (FDA) has approved Rinvoq (upadacitinib; 15mg, once daily) for the treatment of adults with active ankylosing spondylitis (AS) who have had an inadequate response or intolerance to one or more tumor necrosis factor (TNF) blockers, marking the fourth approval for the drug in the past five months alone. 3 May 2022